IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Given Consensus Rating of “Buy” by Analysts

Shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA) have received a consensus recommendation of “Buy” from the thirteen research firms that are covering the company, MarketBeat Ratings reports. Thirteen equities research analysts have rated the stock with a buy rating. The average 1 year price objective among brokerages that have covered the stock in the last year is $44.55.

A number of research firms have commented on IDYA. Royal Bank of Canada lifted their target price on IDEAYA Biosciences from $43.00 to $53.00 and gave the stock an “outperform” rating in a report on Wednesday, February 21st. BTIG Research assumed coverage on IDEAYA Biosciences in a research report on Friday, March 8th. They set a “buy” rating and a $55.00 price objective on the stock. The Goldman Sachs Group lifted their price objective on IDEAYA Biosciences from $36.00 to $53.00 and gave the stock a “buy” rating in a report on Thursday, January 25th. JPMorgan Chase & Co. upped their target price on shares of IDEAYA Biosciences from $51.00 to $57.00 and gave the company an “overweight” rating in a research note on Friday, February 23rd. Finally, Citigroup lifted their price target on shares of IDEAYA Biosciences from $40.00 to $60.00 and gave the stock a “buy” rating in a research note on Thursday, March 21st.

Insider Activity at IDEAYA Biosciences

In related news, insider Briseno Andres Ruiz sold 2,000 shares of the firm’s stock in a transaction on Monday, January 22nd. The stock was sold at an average price of $42.03, for a total value of $84,060.00. Following the transaction, the insider now directly owns 26,531 shares of the company’s stock, valued at approximately $1,115,097.93. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. In other news, CEO Yujiro S. Hata sold 23,557 shares of the stock in a transaction on Friday, February 9th. The shares were sold at an average price of $45.54, for a total value of $1,072,785.78. Following the completion of the sale, the chief executive officer now directly owns 677,887 shares of the company’s stock, valued at $30,870,973.98. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Briseno Andres Ruiz sold 2,000 shares of IDEAYA Biosciences stock in a transaction on Monday, January 22nd. The shares were sold at an average price of $42.03, for a total transaction of $84,060.00. Following the transaction, the insider now owns 26,531 shares in the company, valued at approximately $1,115,097.93. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 27,557 shares of company stock worth $1,248,886. 5.00% of the stock is owned by company insiders.

Institutional Investors Weigh In On IDEAYA Biosciences

Institutional investors have recently bought and sold shares of the business. Walleye Capital LLC bought a new position in shares of IDEAYA Biosciences in the third quarter worth about $2,265,000. Boone Capital Management LLC boosted its stake in IDEAYA Biosciences by 15.0% in the 3rd quarter. Boone Capital Management LLC now owns 570,682 shares of the company’s stock worth $15,397,000 after purchasing an additional 74,249 shares during the period. Barclays PLC grew its holdings in IDEAYA Biosciences by 17.8% during the 3rd quarter. Barclays PLC now owns 86,326 shares of the company’s stock valued at $2,330,000 after buying an additional 13,049 shares in the last quarter. Eventide Asset Management LLC bought a new stake in shares of IDEAYA Biosciences during the third quarter valued at approximately $9,038,000. Finally, China Universal Asset Management Co. Ltd. raised its position in shares of IDEAYA Biosciences by 405.6% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 7,453 shares of the company’s stock valued at $265,000 after buying an additional 5,979 shares during the last quarter. Hedge funds and other institutional investors own 98.29% of the company’s stock.

IDEAYA Biosciences Price Performance

Shares of IDEAYA Biosciences stock opened at $41.17 on Wednesday. IDEAYA Biosciences has a 1 year low of $13.81 and a 1 year high of $47.74. The firm’s 50-day moving average is $44.25 and its 200 day moving average is $36.91. The stock has a market cap of $3.07 billion, a price-to-earnings ratio of -20.90 and a beta of 0.80.

IDEAYA Biosciences (NASDAQ:IDYA) last issued its earnings results on Tuesday, February 20th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.47) by ($0.05). The firm had revenue of $3.90 million during the quarter, compared to analysts’ expectations of $8.84 million. IDEAYA Biosciences had a negative return on equity of 23.00% and a negative net margin of 483.05%. The firm’s revenue was down 3.0% compared to the same quarter last year. On average, equities analysts expect that IDEAYA Biosciences will post -2.26 EPS for the current fiscal year.

IDEAYA Biosciences Company Profile

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.